Davita Inc.
DVA · NYSE · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Davita Inc. at a glance
In FY2025, Davita Inc. reported revenue of USD 13,643,069 thousands, EBITDA of USD 12,605,322 thousands, EBITDA margin of 92.4%.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 12,815,550 | 13,643,069 | |||
| EBITDA | 11,832,384 | 12,605,322 | |||
| EBITDA margin | 92.3% | 92.4% | |||
| Free cash flow | 1,466,595 | 1,310,636 | |||
| ROIC | 109.2% | 117.7% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas